Iodosorb, Cadexomer Iodine Medicated Ointment, 10g tube - Pkt/4
RRP: $231.80 $181.24 inc GST Save: $50.56
Vital Medical Supplies
Infection Management
Chronic wounds account for approximately 400,000 medical incidents each year at an estimated cost of $2.85 billion. If left untreated, infected chronic wounds can have serious negative impacts on patients' health and quality of life in areas such as comfort, mobility, appetite and lifestyle.
Early intervention can reduce the burden of chronic wounds on patients and the healthcare system.
IODOSORB
IODOSORB is indicated for use in chronic and infected wounds where bioburden is a barrier to healing.
IODOSORB◊ is a dual-action wound management product that offers the benefits of a broad-spectrum, sustained-activity antimicrobial agent 5,6,7 in combination with desloughing and fluid-handling properties,15 making it effective against biofilm in vitro and in vivo.1,2-4
IODOSORB is a unique antimicrobial agent made of cadexomer ‘smart’ micro-beads: spherical starch structures loaded with 0.9% elemental iodine. The iodine is physically bound to the bead and provides sustained release when the bead comes into contact with wound fluid. 8-10
Features and Benefits
Absorbs
IODOSORB is highly absorbent to manage exudate and achieve moisture balance.16
Disrupts
IODOSORB has been shown to disrupt biofilms of Pseudomonas aeruginosa and Staphylococcus aureus in chronic wounds.17
Reduces
IODOSORB reduces bioburden and infection for up to 72 hours.15
Desloughs
IODOSORB possesses rapid desloughing capabilities to clear chronic wounds of debris and facilitate healing.15
**Important Information about IODOSORB**
The decision to use IODOSORB should be made by a healthcare professional, in line with applicable local protocols. Smith+Nephew products should always be used for the indications set out in the applicable Instructions for use.
For detailed product information, including indications for use, contraindications, effects, precautions, warnings, and important safety information, please always consult product’s Instructions For Use (IFU) prior to use.
ACTICOAT
ACTICOAT has a unique nanocrystalline structure12 with a high surface area of silver - enabling more bactericidal silver13 to come into contact with a wound fluid.
ACTICOAT delivers enough silver, quickly, to sustain the concentration of Ag+ needed to be bactericidal. 14
Features and Benefits
Fast Acting
Kills bacteria (in vitro) within 30 minutes.11
Broad Spectrum
ACTICOAT is effective against 150+ pathogens including MRSA, VRE, CRE and yeasts.12
Sustained release of silver
ACTICOAT consistently disperses silver for up to 3 or 7 days.
**Important Information about ACTICOAT**
The decision to use ACTICOAT should be made by a healthcare professional, in line with applicable local protocols. Smith+Nephew products should always be used for the indications set out in the applicable Instructions for use.
For detailed product information, including indications for use, contraindications, effects, precautions, warnings, and important safety information, please always consult product’s Instructions For Use (IFU) prior to use.
Buy Iodosorb Online
S&N IODOSORB, Cadexomer Iodine Powder, 3g Pack - Box of 7
RRP: $138.29 $108.02 inc GST Save: $30.27
Buy Acticoat Online
S&N Acticoat 3 DayDressing 10x10cm - Box/5
RRP: $331.60 $259.33 inc GST Save: $72.27
S&N Acticoat 3 Day Dressing 5x5cm - Box/5
RRP: $177.21 $140.42 inc GST Save: $36.79
S&N Acticoat Flex 3 10x10cm - Box/5
RRP: $331.60 $265.47 inc GST Save: $66.13
S&N Acticoat Flex 3 5x5cm - Box/5
RRP: $177.21 $145.39 inc GST Save: $31.82
PDFs and Videos
Frequently Asked Questions
References
1. Phillips PL, et al. Antimicrobial dressing efficacy against mature Pseudomonas aeruginosa biofilm on porcine skin explants. Int. Wound J. 469–483
(2013). doi:10.1111/iwj.12142.
2. Fitzgerald DJ, et al. Cadexomer iodine provides superior efficacy against bacterial wound biofilms in vitro and in vivo. Wound Repair
Regen. 25, 13–24 (2017).
3. Roche ED, et al. Cadexomer iodine effectively reduces bacterial biofilm in porcine wounds ex vivo and in vivo. Int. Wound J. 1–10 (2019). doi:10.1111/iwj.13080
4. Malone M, et al. Effect of cadexomer iodine on the microbial
load and diversity of chronic non-healing diabetic foot ulcers complicated by biofilm in vivo. J. Antimicrob. Chemother. 72, 2093–2101 (2017).
5. Forest E. Antimicrobial activity of IODOSORB range against a broad spectrum of wound pathogens. Smith & Nephew Data on File #1801001. (2018).
6. Harrow J. A comparison of the antimicrobial activity of a cadexomer iodine dressing and a povidone iodine dressing. 6763/IODOSORB/TECHMON/GLOBAL/0404. (2009).
7. Forest, E. Antimicrobial activity of IODOSORB range in a 3 day repeat challenge model. Smith & Nephew Data on File #1801002. V2. (2018).
8. Hesler B. Release of iodine from IODOSORB/IODOFLEX Dressing into 0.9% saline solution over a three day period. Smith& Nephew Data on File # DS.18.026.R. (2018).
9. Hesler B. Release of iodine from IODOSORB Powder into 0.9% saline solution over a three day period. Smith & Nephew Data on File # DS.18.024.R. (2018).
10. Hesler B. Release of iodine from IODOSORB Ointment into 0.9% saline solution over a three day period. Smith & Nephew Data on File # DS.18.025.R. (2018).
11. Driffield K, Woodmansey E, Floyd H. The use of silver-containing dressings to prevent biofilm formation by single and mixed bacterial flora. in SAWC (2007).
12.Wright JB, Lam K, Hansen D, Burrell RE. Efficacy of topical silver against fungal wound pathogens. American Journal of Infection Control 1999;27(4):344-50
13. West P, Gunning P. Visualisation of silver levels in 2 silver dressings using scanning electron microscopy and energy dispersive X ray microanalysis. Poster presented at SAWC meeting San Antonio 2006.
14. Woodmansey E. Comparison of the speed of kill of pathogenic bacteria using ACTICOAT and AQUACEL(TM) Ag analysed using confocal laser scanning microscopy. In: Nephew Sa, editor. York Data on file; 2005: report 0505004.
15. Sundberg J, Pharm MS, Meller R, Se B, Pharm MS. A retrospective review of the use of cadexomer iodine in the treatment of chronic wounds. Wounds A Compend. Clin. Res. Pract. 9, 68–86 (1997).
16.Skog E, et al. A randomized trial comparing cadexomer iodine and standard treatment in the out-patient management of chronic venous ulcers. Br. J. Dermatol. 109, 77–83 (1983)
17.Akiyama H, Oono T, Saito M, Iwatsuki K. Assessment of cadexomer iodine against Staphylococcus aureus biofilm in vivo and in vitro using confocal laser scanning microscopy. J. Dermatol. 31, 529–34 (2004)